VA awards McKesson Corporation $1.02B for pharmaceutical prime vendor services in FY2025

Contract Overview

Contract Amount: $1,020,312,793 ($1.0B)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2025-06-01

End Date: 2025-06-30

Contract Duration: 29 days

Daily Burn Rate: $35.2M/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 JUNE

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $1.02 billion to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 JUNE Key points: 1. This contract represents a significant portion of the VA's pharmaceutical spending. 2. The firm fixed-price contract type aims to control costs for the government. 3. The short duration of the delivery order suggests it may be for immediate or specific needs. 4. The award is to a large, established pharmaceutical distributor. 5. Competition dynamics for this type of large-scale prime vendor contract can be limited. 6. Performance will be critical to ensuring timely access to essential medications for veterans.

Value Assessment

Rating: good

The VA's Pharmaceutical Prime Vendor (PPV) program is a critical component of its healthcare system, ensuring access to a wide range of medications. While the total award amount is substantial, it reflects the scale of pharmaceutical distribution required for a large federal agency. Benchmarking this specific delivery order against the overall PPV program's annual spending or against similar large-scale distribution contracts would provide a clearer picture of value for money. The firm fixed-price structure is a positive indicator for cost control.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under full and open competition, indicating that multiple vendors had the opportunity to bid. However, the nature of large-scale pharmaceutical prime vendor contracts often means that only a few major distributors possess the infrastructure and capacity to fulfill such requirements. The specific number of bidders for this delivery order is not provided, but the full and open designation suggests a competitive process was initiated.

Taxpayer Impact: Full and open competition is generally favorable for taxpayers as it encourages multiple vendors to offer competitive pricing, potentially leading to better value. It ensures that the government is not locked into a single provider without exploring other options.

Public Impact

Veterans will benefit from continued access to a broad formulary of pharmaceuticals. The Department of Veterans Affairs will receive essential pharmaceutical distribution services. The contract supports the VA's mission to provide comprehensive healthcare to veterans. The delivery order is specific to Texas, impacting healthcare providers and facilities within that state. This contract supports jobs within the pharmaceutical distribution and logistics sectors.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for price increases in future contract periods if competition becomes more limited.
Dependence on a single large contractor for a critical supply chain function.
Ensuring consistent product availability and quality across all dispensed medications.

Positive Signals

Firm fixed-price contract helps manage cost certainty.
Awarded under full and open competition, suggesting a competitive bidding process.
The contractor, McKesson Corporation, is a major player with extensive experience in pharmaceutical distribution.

Sector Analysis

The pharmaceutical distribution sector is a vital part of the healthcare industry, responsible for the timely and efficient delivery of medications from manufacturers to healthcare providers. This contract falls within the broader healthcare services and logistics market. The market is characterized by a few large national distributors that handle the majority of pharmaceutical supply chain operations for both government and commercial entities. The scale of this award is significant within the context of federal pharmaceutical procurement.

Small Business Impact

This contract does not appear to have a small business set-aside. Given the scale and specialized nature of pharmaceutical prime vendor services, it is unlikely that small businesses would be primary awardees for such a large contract. However, the prime contractor, McKesson Corporation, may engage small businesses for subcontracting opportunities related to logistics, transportation, or administrative support within its operations.

Oversight & Accountability

The Department of Veterans Affairs has established oversight mechanisms for its contracts, including performance monitoring and quality assurance processes. The firm fixed-price contract type provides a degree of cost control. Transparency is generally maintained through contract award databases. The VA Office of Inspector General would have jurisdiction to investigate any potential fraud, waste, or abuse related to this contract.

Related Government Programs

VA Federal Supply Schedule (FSS) for Pharmaceuticals
DoD TRICARE Pharmacy Program
GSA Federal Supply Schedules

Risk Flags

Potential for supply chain disruption
Dependence on large prime vendor
Price volatility of pharmaceuticals

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $1.02 billion to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2025 JUNE

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $1.02 billion.

What is the period of performance?

Start: 2025-06-01. End: 2025-06-30.

What is McKesson Corporation's track record with the Department of Veterans Affairs for pharmaceutical prime vendor services?

McKesson Corporation has a long-standing relationship with the Department of Veterans Affairs as a prime vendor for pharmaceuticals. They are one of the major distributors that the VA relies upon to supply medications to its network of healthcare facilities. Historical data indicates McKesson has been a consistent awardee for such services, often competing for and winning significant portions of the VA's pharmaceutical prime vendor contracts. Their extensive experience in managing complex pharmaceutical supply chains and their established infrastructure are key factors in their continued success in securing these awards. The VA's performance evaluations and contract histories would provide specific details on their performance, including on-time delivery rates, order accuracy, and responsiveness to VA requirements over various contract periods.

How does the pricing of this delivery order compare to similar pharmaceutical distribution contracts awarded by the VA or other federal agencies?

Benchmarking the pricing of this specific delivery order requires access to detailed pricing structures and unit costs, which are often not publicly disclosed in full. However, the contract is a firm fixed-price award, which is designed to provide cost certainty to the government. The total award amount of $1.02 billion for a one-month period (June 2025) suggests a high volume of pharmaceutical products being distributed. Comparisons would ideally be made against other VA Pharmaceutical Prime Vendor (PPV) contracts, especially those with similar scope and duration, or against similar large-scale pharmaceutical distribution contracts awarded to other federal agencies like the Department of Defense. Factors such as the specific formulary covered, delivery locations, and service level agreements would influence price comparisons. The competitive nature of the award process, even if only a few large players participate, is intended to drive competitive pricing.

What are the primary risks associated with this contract, and how are they being mitigated?

The primary risks associated with this contract revolve around supply chain disruptions, potential price volatility for pharmaceuticals, and ensuring consistent product availability and quality. A significant risk is the dependence on a single large contractor for a critical function; any failure in McKesson's distribution network could impact the VA's ability to provide medications. Mitigation strategies include the firm fixed-price contract, which caps costs for the government, and the full and open competition requirement, which encourages multiple vendors to maintain high service standards. The VA likely has performance metrics and service level agreements in place to monitor McKesson's operations and address any deficiencies promptly. Furthermore, the VA may maintain contingency plans or alternative sourcing strategies for critical medications to mitigate the impact of any unforeseen disruptions.

What is the expected program effectiveness and impact of this contract on veteran healthcare delivery?

The expected program effectiveness of this contract is high, as it ensures the continued and reliable supply of pharmaceuticals to VA healthcare facilities. By outsourcing the complex logistics of pharmaceutical distribution to a specialized prime vendor like McKesson, the VA can focus its resources on direct patient care. The impact on veteran healthcare delivery is significant: veterans will have timely access to the medications prescribed by their VA physicians, which is crucial for managing chronic conditions, treating acute illnesses, and maintaining overall health and well-being. The efficiency of the distribution network directly translates to fewer stock-outs and delays, improving patient adherence to treatment plans and contributing to better health outcomes for the veteran population served by the VA.

How has federal spending on pharmaceutical prime vendor services evolved over recent years, and where does this award fit in?

Federal spending on pharmaceutical prime vendor services has been substantial and generally increasing over recent years, driven by the growing healthcare needs of federal beneficiaries, including veterans and military personnel. Agencies like the Department of Veterans Affairs and the Department of Defense are major consumers of these services. The VA's Pharmaceutical Prime Vendor (PPV) program, in particular, represents a significant portion of this spending. Awards for PPV contracts are typically large, often in the hundreds of millions or billions of dollars annually, reflecting the scale of pharmaceutical procurement. This $1.02 billion award for a single month's delivery order for FY2025 is a substantial allocation, but it aligns with the historical spending patterns for large-scale pharmaceutical distribution services required by the VA. It indicates a continued reliance on established prime vendors to manage the complex pharmaceutical supply chain.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $1,020,312,793

Exercised Options: $1,020,312,793

Current Obligation: $1,020,312,793

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL PRODUCTS/SERVICES

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline